<DOC>
	<DOCNO>NCT01297101</DOCNO>
	<brief_summary>The aim study investigate efficacy safety Tarceva versus combination Gemcitabine plus Cisplatin neoadjuvant treatment patient stage IIIA-N1 , N2 NSCLC EGFR activate mutation exon 19 21 .</brief_summary>
	<brief_title>Evaluating Efficacy Safety Erlotinib Versus Gemcitabine Plus Cisplatin Neoadjuvant Chemotherapy</brief_title>
	<detailed_description>Concurrent Chemoradiation therapy remain standard treatment stage IIIA disease , treatment-related life threaten toxicity limit use patient . Tarceva monotherapy demonstrate significant improvement overall survival disease progression free survival use treatment patient metastatic NSCLC , failure least one prior chemotherapy regimen . It well tolerate without side effect usually associate chemotherapy . Based encouraging result report SLCG phase II study report efficacy Tarceva first line treatment metastatic NSCLC EGFR mutation patient would prolong overall survival , delay disease progression well tolerate , mOS reach 27 month , ORR reach 71 % . Besides , different mechanism tolerable chemo , Tarceva may provide important treatment alternative local advance pt EGFR mutation .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Pathologically diagnose nonsmall cell lung cancer Diagnosed stage IIIANI , N2 , except T4N1M0 The diagnosis standard N1 N2 : The short axis N1 lymph node Stage IIIAN1 must ≥ 10 mm Computed Tomography , Standard Uptake Value ( SUV ) PETCT N1 lymph node must ＞ 2.5 Patients prior exposure agent direct HER axis ( e.g . erlotinib , gefitinib , cetuximab , trastuzumab ) Patients prior chemotherapy therapy systemic antitumour therapy ( e.g . monoclonal antibody therapy ) Resection primary malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>